InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,433.74
(
0.23%
)
US TECH 100
19,035.20
(
-0.18%
)
Dow Jones
38,647.10
(
-0.17%
)
Brent Oil
82.43
(
0.56%
)
Bitcoin
66,841.59
(
0.13%
)
Post# of 252169
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119832
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 176774

Thursday, 01/29/2015 6:29:59 PM

Thursday, January 29, 2015 6:29:59 PM

Post# of 252169
BMY/GILD—FDA approves Evotaz FDC (Reyataz + Cobicstat):

http://finance.yahoo.com/news/u-food-drug-administration-approves-221900783.html

GILD’s Cobicstat (a constituent of Stribild and Complera) is an alternative to ritonavir for boosting BMY’s HIV protease inhibitor, Reyataz.

BMY will book sales of Evotaz; the companies haven’t disclosed how much GILD will be paid for the Cobicstat component.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up